Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib PK in Severe Renal Impairment
NCT02923947Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of osimertinib in solid tumor (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity at Day 1 and Maximum plasma concentration at Day 1. Started May 2017; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02923947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923947.